PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.535 AUD 3.02% Market Closed
Market Cap: 895.3m AUD

PYC Therapeutics Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

PYC Therapeutics Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
PYC Therapeutics Ltd
ASX:PYC
Revenue
AU$26.2m
CAGR 3-Years
18%
CAGR 5-Years
59%
CAGR 10-Years
41%
Opthea Ltd
ASX:OPT
Revenue
$25k
CAGR 3-Years
-35%
CAGR 5-Years
-16%
CAGR 10-Years
-30%
Mesoblast Ltd
ASX:MSB
Revenue
$17.2m
CAGR 3-Years
19%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
CSL Ltd
ASX:CSL
Revenue
$15.6B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
11%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Revenue
AU$95m
CAGR 3-Years
13%
CAGR 5-Years
23%
CAGR 10-Years
38%
Telix Pharmaceuticals Ltd
ASX:TLX
Revenue
AU$507.9m
CAGR 3-Years
306%
CAGR 5-Years
171%
CAGR 10-Years
N/A
No Stocks Found

PYC Therapeutics Ltd
Glance View

Market Cap
900.2m AUD
Industry
Biotechnology

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.

PYC Intrinsic Value
5.261 AUD
Undervaluation 71%
Intrinsic Value
Price

See Also

What is PYC Therapeutics Ltd's Revenue?
Revenue
26.2m AUD

Based on the financial report for Jun 30, 2025, PYC Therapeutics Ltd's Revenue amounts to 26.2m AUD.

What is PYC Therapeutics Ltd's Revenue growth rate?
Revenue CAGR 10Y
41%

Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for PYC Therapeutics Ltd have been 18% over the past three years , 59% over the past five years , and 41% over the past ten years .

Back to Top